Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom

OBJECTIVE: To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2−) advanced breast cancer from a UK payer perspective. METHODS: A cohort-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2019
Materias:
General Indications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299496/
https://www.ncbi.nlm.nih.gov/pubmed/32685577
http://dx.doi.org/10.36469/9725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299496/
https://www.ncbi.nlm.nih.gov/pubmed/32685577
http://dx.doi.org/10.36469/9725

Ejemplares similares